Literature DB >> 31481799

Daratumumab for treatment of pure red cell aplasia after allogeneic stem cell transplantation.

Christina Rautenberg1, Jennifer Kaivers1, Ulrich Germing1, Rainer Haas1, Stefanie Ackerstaff2, Till Hoffmann2, Guido Kobbe1, Thomas Schroeder3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31481799     DOI： 10.1038/s41409-019-0664-4

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  3 in total

Review 1.  Pure red cell aplasia after major or bidirectional ABO incompatible hematopoietic stem cell transplantation: to treat or not to treat, that is the question.

Authors:  Javier Marco-Ayala; Inés Gómez-Seguí; Guillermo Sanz; Pilar Solves
Journal:  Bone Marrow Transplant       Date:  2020-11-14       Impact factor: 5.483

2.  Daratumumab as a Frontline Immunosuppression for Pure Red Cell Aplasia after Major ABO-mismatched Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Thiti Asawapanumas; Chantiya Chanswangphuwana; Phandee Watanaboonyongcharoen; Ponlapat Rojnuckarin; Udomsak Bunworasate
Journal:  Leuk Res Rep       Date:  2022-04-13

3.  Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from two pediatric cases and review of literature.

Authors:  Lina Driouk; Robert Schmitt; Anke Peters; Sabine Heine; Hermann Josef Girschick; Brigitte Strahm; Charlotte M Niemeyer; Carsten Speckmann
Journal:  Mol Cell Pediatr       Date:  2021-04-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.